We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New Test Detects Parasite Responsible for Trichomoniasis Infection In 15 Minutes

By LabMedica International staff writers
Posted on 27 Feb 2025
Print article
Image: The new test will make it possible to detect the parasite responsible for trichomoniasis much more quickly and inexpensively (Photo courtesy of Universitat Rovira i Virgili)
Image: The new test will make it possible to detect the parasite responsible for trichomoniasis much more quickly and inexpensively (Photo courtesy of Universitat Rovira i Virgili)

Trichomoniasis is one of the most prevalent sexually transmitted infections globally. It is caused by the parasite Trichomonas vaginalis, which is often difficult to detect as the infection is frequently asymptomatic, making diagnosis and treatment challenging. Early detection is crucial, as untreated infections can lead to reproductive health issues, increase the likelihood of HIV transmission, and cause genital tract inflammation. In response to this challenge, researchers have developed a rapid, cost-effective, and easy-to-use test for detecting the parasite. The findings from this research were published in Sensors & Diagnostics.

The test, called ALFA (Aptamer-based Lateral Flow Assay), was developed by a team from Universitat Rovira i Virgili (Tarragona, Spain) using innovative DNA aptamer technology. Aptamers are short nucleic acid sequences that can bind highly specifically to target molecules. The test employs a dual aptamer system: one aptamer is immobilized on a nitrocellulose membrane as a capturer, and the other is linked to gold nanoparticles, which generate a visual detection signal. This design helps to reduce production costs and enhances the stability of the test. One of the key benefits of this test is its affordability, costing under one euro. This makes it a viable tool for use in public health initiatives and in countries with limited healthcare resources.

The researchers demonstrated that the test can detect very low concentrations of the parasite without being confused by other common vaginal microorganisms, ensuring its accuracy. Stability is another significant advantage, as the test components retain their effectiveness for up to a year at room temperature (22 ºC), eliminating the need for refrigeration or special packaging. This feature makes the test suitable for distribution in resource-limited areas. Furthermore, the test is straightforward to use, requiring only three simple steps from sample collection to result, which can be obtained in about 15 minutes. In initial trials using clinical samples, the results were consistent with those obtained through the traditional method of direct observation. The research team plans to continue expanding its approach to detect other pathogens in the future.

Related Links:
Universitat Rovira i Virgili

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Hemoglobin/Haptoglobin Assay
IDK Hemoglobin/Haptoglobin Complex ELISA
New
HbA1c Test
HbA1c Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: Professor Nicole Strittmatter (left) and first author Wei Chen stand in front of the mass spectrometer with a tissue sample (Photo courtesy of Robert Reich/TUM)

Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication

Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.